Ohio Medicaid does not cover Zepbound for weight loss. The exclusion is categorical: tirzepatide prescribed for obesity is a non-covered drug under state rules, and no prior authorization pathway exists to request an exception, regardless of your BMI or weight-related conditions.
Why the Exclusion Exists
The rule driving this is Ohio Administrative Code 5160-9-03, which classifies drugs prescribed to treat obesity as non-covered and ineligible for prior authorization.1Ohio Legislative Service Commission. Rule 5160-9-03 Pharmacy Services: Covered Drugs and Associated Limitations Federal law permits this. Although the Medicaid Drug Rebate Program generally requires states to cover FDA-approved outpatient drugs, weight-loss medications sit inside a statutory carve-out that lets states opt out.2KFF. Medicaid Coverage of and Spending on GLP-1s Ohio has used that option for years and continues to do so.
Ohio is in the majority on this. As of January 2026, only 13 state Medicaid programs covered GLP-1 drugs for obesity, and the count has been shrinking: California, New Hampshire, Pennsylvania, and South Carolina all dropped coverage in late 2025 or early 2026 because of cost.2KFF. Medicaid Coverage of and Spending on GLP-1s
What Ohio Medicaid Will Cover for Related Conditions
Tirzepatide is not shut out of Ohio Medicaid entirely. The same molecule is sold as Mounjaro for Type 2 diabetes, and Mounjaro appears on the Ohio Medicaid Unified Preferred Drug List with prior authorization required.3PlexusDx. GLP-1 in Ohio Prescribers submit requests through Ohio’s Single Pharmacy Benefit Manager, Gainwell Technologies. A November 2025 Gainwell notice stated plainly that preferred GLP-1 coverage requires a documented Type 2 diabetes diagnosis, and that “for all other non-FDA approved uses (such as prediabetes or weight loss), coverage will not be available.”4Ohio Medicaid SPBM. Single Pharmacy Benefit Manager Public Portal
In April 2026, Ohio Medicaid added coverage for Wegovy under a new therapeutic class covering GLP-1 agonists for non-obesity indications. The coverage reaches two situations:
- Cardiovascular risk reduction for adults 18 and older with a BMI of at least 27 and a history of heart attack, stroke, or symptomatic peripheral artery disease, who do not have Type 1 or Type 2 diabetes and are already on standard cardiovascular medications.
- Metabolic dysfunction-associated steatohepatitis (MASH) in adults with noncirrhotic disease confirmed by liver biopsy within the past 24 months or by specific diagnostic criteria showing moderate to advanced fibrosis.
Both routes require clinical prior authorization. Continued coverage after the initial authorization requires at least 5% weight loss from baseline and documented treatment adherence.5Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes This expansion covers Wegovy (semaglutide), not Zepbound (tirzepatide), so it does not open a coverage door for Zepbound even for these conditions.
The Sleep Apnea Gap
Zepbound received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, becoming the first medication approved for that condition.6U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea7Eli Lilly and Company. FDA Approves Zepbound (Tirzepatide) for Obstructive Sleep Apnea Because sleep apnea is not a weight-loss indication, federal Medicaid rules would generally require states to cover the drug for this use.
Ohio has not operationally caught up. As of mid-2026, reporting on Ohio’s GLP-1 landscape notes that “standard coverage for indications such as Obstructive Sleep Apnea remains unavailable” despite the FDA approval.8PlexusDx. GLP-1 in Ohio If you have a sleep apnea diagnosis and your prescriber believes you qualify, the gap between the federal rule and Ohio’s practice is at least a plausible basis for a prior authorization request and, if denied, an appeal.
If You Want Zepbound Anyway
For a weight-loss prescription, there is no appeal to pursue inside Medicaid. The exclusion is categorical, so there are no clinical criteria to meet. For a non-obesity use like sleep apnea, the pathway looks like this:
- Your prescriber submits a prior authorization request to Gainwell Technologies electronically or by fax. Decisions arrive within 24 hours.4Ohio Medicaid SPBM. Single Pharmacy Benefit Manager Public Portal
- If the request is denied, you receive a formal notice with the reason and appeal instructions.9Disability Rights Ohio. Medicaid Prior Authorization
- The appeal process differs for managed care versus fee-for-service enrollees; the denial notice sets the timeline and steps. Disability Rights Ohio publishes guidance for people who need help with Medicaid appeals.
Paying out of pocket is the realistic route for weight loss. Eli Lilly’s LillyDirect self-pay program offers Zepbound vials starting at $299 per month for the lowest dose and $449 per month for 7.5 mg and above.10Eli Lilly. Zepbound Savings List pricing without the self-pay program runs from $499 to over $1,086 per fill.11Eli Lilly. Zepbound Pricing Information One important limit: Medicaid enrollees are not eligible for Lilly’s savings card, which is restricted to patients with commercial insurance or no insurance. Zepbound is also not part of the Lilly Cares patient assistance program.
The federal TrumpRx platform, launched in early 2026, sells Zepbound directly to consumers starting at $350 per month with no insurance or income requirements, with prices projected to fall toward $245 per month over two years.12CNBC. Trump Eli Lilly Novo Nordisk Deal Obesity Drug Prices For a Medicaid enrollee set on Zepbound for weight loss, this is likely the most accessible paid route.
Is This Likely To Change
Three federal moves could eventually push Ohio to cover Zepbound for weight loss, but none has forced the issue so far.
CMS announced the BALANCE model in December 2025, a voluntary five-year program to negotiate lower manufacturer prices for obesity drugs and expand Medicaid and Medicare access. States were asked to signal participation by January 8, 2026, with a May 2026 launch.2KFF. Medicaid Coverage of and Spending on GLP-1s Participation is voluntary and the available reporting does not indicate Ohio has opted in.
The Trump administration’s agreement with Eli Lilly and Novo Nordisk extends “most-favored-nation” pricing to state Medicaid programs, with GLP-1 medications priced at $245 per month for non-starting doses.13The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most Favored Nation Pricing to American Patients States still have to opt in, and a lower price does not override the Ohio Administrative Code provision excluding obesity drugs.12CNBC. Trump Eli Lilly Novo Nordisk Deal Obesity Drug Prices
CMS has also proposed a rule (CMS-4208-P) that would mandate state Medicaid coverage of anti-obesity medications. The National Association of Medicaid Directors has objected, asking for at least a two-year implementation window.14National Association of Medicaid Directors. Optional Not Mandatory: NAMDs Recommendations on Anti-Obesity Medication Coverage As of mid-2026, the rule remains a proposal. Until one of these mechanisms actually compels coverage, Ohio’s exclusion of Zepbound for weight loss stands.